The study of six types of mental illnesses in a thousand brain regions has demonstrated the differences between individuals within each disorder. Using magnetic resonance images (MRI), scientists from Monash University in Australia analyzed the brain changes and built individual maps for each psychiatric disorder. Their results revealed differences between people with the same diagnosis, which could help refine assessments. Read More
Research in rhesus monkeys has shown a gene therapy that enhanced activity in dopamine producing neurons in the brain was effective at stopping excessive alcohol consumption in previously addicted animals. Read More
Novarock Biotherapeutics Ltd., a subsidiary of CSPC Pharmaceutical Group Ltd., has received FDA approval of its IND application for NBL-028, a CLDN6-CD137 bispecific antibody. Read More
Researchers working at the Lady Davis Institute, Jewish General Hospital, McGill University, have combined whole-exome sequencing (WES) from nearly 300,000 samples from the multiancestry UK Biobank, with ultrasound-derived heel estimated bone mineral density (eBMD) and genome-wide association (GWAS) data to identify potential future therapeutic targets for patients with osteoporosis. Read More
Researchers at Foshan Ionova Biotherapeutics Co. Ltd. and Shenzhen Ionova Life Science Co. Ltd. have disclosed fused heterocyclic compounds acting as RAS modulators reported to be useful for the treatment of cancer. Read More
Tumor necrosis factor-α (TNF-α) is a cytokine involved in the regulation of inflammation in several autoimmune and inflammatory disorders such as rheumatoid arthritis, ulcerative colitis, or psoriasis. Anti-TNF biological treatments in place are effective but there is a need for alternatives with novel pharmacological profiles to overcome their limitations. Read More
Onsero Therapeutics Inc. has synthesized 5-HT2A receptor agonists reported to be useful for the treatment of depression, anxiety, substance abuse and dependence, and headache. Read More
Maze Therapeutics Inc. has identified apolipoprotein L1 (APOL1) inhibitors reported to be useful for the treatment of chronic kidney disease, focal segmental glomerulosclerosis, diabetic, hypertensive, HIV-associated nephropathy, lupus nephritis, pre-eclampsia and sepsis. Read More
China Pharmaceutical University has divulged pyridoimidazole compounds acting as NLRP3 inflammasome and IL-1β (IL1B; IL-1β) inhibitors reported to be useful for the treatment of atherosclerosis, diabetes, neurodegeneration, gout, rheumatoid arthritis, chronic kidney, inflammatory bowel, and non-alcoholic fatty liver disease (NAFLD), among others. Read More
Aurigene Oncology Ltd. has described substituted bicyclic heterocycles acting as mucosa associated lymphoid tissue lymphoma translocation protein 1 (MALT1) inhibitors reported to be useful for the treatment of cancer, rheumatoid arthritis, ulcerative colitis, asthma, psoriatic arthritis, chronic obstructive pulmonary disease (COPD), psoriasis and systemic lupus erythematosus (SLE), among others. Read More
Targeting the adenosine A2A receptor, a critical mediator of immunosuppression on the tumor microenvironment, has emerged as a strategy to improve cancer immunotherapy, and several A2A receptor antagonists are under clinical evaluation both as monotherapy and in combination with checkpoint inhibitors. Read More
